21-Oct-2019
3 Stocks Moving On FDA Verdicts: Alexion, AstraZeneca, Foamix
Benzinga 21-Oct 12:42 PM
Earnings Season Kicks Into Full Gear In Round 3 Of The WeTrader Competition
Benzinga 21-Oct 11:16 AM
FDA OKs expanded indication for AstraZeneca's Farxiga
Seeking Alpha 21-Oct 10:55 AM
Business Wire 21-Oct 7:00 AM
Valuation Ratios | AZN | Peers |
---|---|---|
P/E Ratio:
Ratio Price/Earnings. Common valuation ratio measures the price of the stock relative to how much earnings the company generates per share. |
51.83 | |
P/E Normalized EPS:
Price/TTM normalized diluted earnings per share. This calculation reverses the effects of extraordinary income or charges on Net Income, by adding back (extraordinary expense) or subtracting (extraordinary income) the value from Net Income |
-1.55 | |
Price/Sales:
Ratio Price/Revenue |
4.85 | |
Price/Book Value:
Ratio Price/Book Value. Book Value is Common Shareholder’s Equity / Diluted Shares Outstanding. |
8.47 | |
Price/Tangible Book Value:
Ratio price/Tangible book value. Tangible Book Value is The company’s total book value less the value of any intangible assets dividend by number of shares. |
-5.63 | |
PEG Ratio:
Forward PE Ratio / Long-term Average Earning Growth Rate. Peg ratio is a version of a P/E ratio using an estimated forward earnings taking into consideration earnings growth estimates. |
1.96 | |
Price/Cash: | ||
Price/Free Cash Flow:
Ratio Price/Free Cash Flow. Free Cash Flow is Cash Flow Operations plus Capital Expenditures. Free cash flow is the cash from operations left over after the company pays for its operating and capital expenses. |
194.74 | |
Price/Ebitda:
Ratio Price/Ebitda. Ebitda is Earnings minus expenses (excluding interest, tax, depreciation, and amortization expenses). |
||
Price/Ebit:
Ratio Price/Ebit. Ebit is Earnings minus expenses (excluding interest and tax expenses). |
||
Price/Working Capital:
Ratio Price/Working Capital. Working Capital is Current Assets minus Current Liabilities. |
-140.76 | |
Forward PE Ratio:
1 / ForwardEarningYield. Forward Yield: Estimated Earnings Per Share / Price. EPS is estimated for next year. |
22.57 | |
PEG Pay Back:
The number of years it would take for a company's cumulative earnings to equal the stock's current trading price, assuming that the company continues to increase its annual earnings at the growth rate used to calculate the PEG ratio. |
10.75 | |
Price/CFO:
Ratio Price/Cash Flow from Operations: Cash Flow from Operations is the amount of money a company generates on a regular basis from its business activity. Excludes any one time activity. |
47.15 | |
EV to EBITDA:
Ratio Enterprise Value/Earnings Before Interest, Taxes and depreciation and amortization. |
44.83 |
Profit Ratios | AZN | Peers |
---|---|---|
Gross Margin:
Refers to the ratio of gross profit to revenue. (Revenue – Cost of Goods Sold) / Revenue |
78.4% | |
Ebitda Margin:
Refers to the ratio of earnings before interest, taxes and depreciation and amortization to revenue. EBITDA / Revenue |
12.6% | |
Ebit Margin:
Refers to the ratio of earnings before interest and taxes to revenue. EBIT / Revenue |
12.6% | |
Net Profit Margin:
Refers to the ratio of net income to revenue. Net Income / Revenue. |
9.5% | |
Effective Tax Rate:
Refers to the ratio of tax provision to pretax income. Tax Provision / Pretax Income |
24.1% | |
Return on Equity: | 16.2% | |
Sales Per Employee: | 90,139 | |
Pre-Tax Margin:
Refers to the ratio of pretax income to revenue. Pretax Income / Revenue. |
9.1% | |
ROIC:
Return on Invested Capital: Net Income / (Total Equity + Long-term Debt and Capital Lease Obligation + Short-term Debt and Capital Lease Obligation). |
8.8% | |
Normalized Net Profit Margin:
Normalized Income / Total Revenue. A measure of profitability of the company calculated by finding Normalized Net Profit as a percentage of Total Revenues. |
9.5% | |
Operation Margin:
Refers to the ratio of operating income to revenue. Operating Income / Revenue. |
7.1% | |
ROA:
Return on Assets. Net Income / Average Total Assets |
3.5% | |
Cash Return:
Ratio of free cash flow to enterprise value. This number tells you what cash return you would get if you bought the entire company, including its debt. |
0.9% |
Dividend | AZN | Peers |
---|---|---|
Div. Yield: | 3.2% | |
Payout Ratio:
Dividend per share / Diluted earning per share |
162.8% | |
DPS Growth (3yr):
The annualized growth in the company’s dividends per share (DPS) on a percentage basis. |
0.0% |
Leverage Ratios | AZN | Peers |
---|---|---|
Debt/Equity: | 1.45 | |
Debt/Assets: | 0.32 | |
Debt/EBITDA:
Ratio Debt/Earnings before interest, taxes and depreciation and amortization |
||
Debt/Cash: | ||
Interest Coverage:
Ratio of EBIT/Interest Expense. The ability of a company to meet its interest expense. Earnings before interest and taxes (EBIT)/Interest Expense. Healthy > 2 |
1.39 | |
Quick Ratio:
(Cash, Cash Equivalents, and ShortTerm Investments + Receivables ) / Current Liabilities. Healthy > 1 |
0.72 | |
Current Ratio:
Current Assets / Current Liabilities. Healthy > 1.5 |
0.95 | |
Debt/Capital:
Refers to the ratio of Long Term Debt to Total Capital. Long-Term Debt And Capital Lease Obligation / (Long-Term Debt And Capital Lease Obligation + Total Shareholder’s Equity) |
||
Financial Leverage:
Ratio of Total Assets/Common Equity. |
4.57 |
Growth | AZN | Peers |
---|---|---|
Diluted EPS Growth (3yr): | -8.6% | |
Sustainable Growth:
ROE * (1 – Payout Ratio). It refers to a growth rate the company can sustain without having to raise additional capital and increase debt financing. |
-10.1% | |
Revenue Growth (5yr): | -3.0% | |
Operation Income Growth (5yr): | -16.3% | |
Gross Profit Annual 5yr Growth: | -3.5% | |
Capital Expenditure Annual 5yr Growth: | -7.8% | |
Net Income Growth (5yr): | -3.4% |
Averages | AZN | Peers |
---|---|---|
Gross Margin 5-yr avg: | 79.9% | |
Profit Margin 5-yr avg: | 10.9% | |
ROIC 5-yr avg: | 9.9% | |
ROA 5-yr Avg: | 4.2% | |
ROE 5-yr Avg: | 15.5% | |
Working Capital Per Share 5-yr Avg: | -0.72 | |
Tangible BV Per Share 5-yr Avg: | -8.06 | |
PE Ratio 5-yr Avg: | 41.43 |